Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: KBV Research | PRODUCT CODE: 1245508

Cover Image

PUBLISHER: KBV Research | PRODUCT CODE: 1245508

Asia Pacific Onychomycosis Market Size, Share & Industry Trends Analysis Report By Type (Distal Subungual, Proximal Subungual, White Superficial and Others), By Treatment (Topical, Oral and Others), By Country and Growth Forecast, 2022 - 2028

PUBLISHED:
PAGES: 79 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 1500
PDF (Site License)
USD 1800
PDF (Enterprisewide License)
USD 2520

Add to Cart

The Asia Pacific Onychomycosis Market would witness market growth of 5.6% CAGR during the forecast period (2022-2028).

Onychomycosis is frequently thought of as merely a cosmetic issue. However, it can be unpleasant, cause cellulitis in elderly people, and can result in foot ulcers in diabetic patients. The key to enhancing the appearance and preventing these consequences is the eradication of the infection. But this is difficult to do because keratin, the substance that makes up nails and is nonvascular and impervious to many substances, makes it difficult to do. As a result, topical and oral medications are mostly preferred to treat the condition.

The type of treatment depends on the organism involved, how severe the nail alterations are, and any potential side effects or drug interactions. On the basis of cure characteristics that are specified differently between researches, treatments also range in their effectiveness. Recurrent infection is possible even for those who seem to be treated, and it can happen for various reasons. Concomitant disease, genetics, immunosuppression, improper dosage or course of therapy, dampness, occlusive footwear, advanced age, poor cleanliness, tinea pedis, and trauma are some major risk factors.

Controlling the transmission of infectious diseases, such as HIV, continues to be difficult in many Asian countries. New illnesses and drug-resistant forms of health issues are particularly prone to spreading in Southeast Asia. Asia, where over two-thirds of the world's poor reside, nevertheless experiences food insecurity. Southeast Asia is experiencing rapid changes in its population, agriculture, and food systems, which have led to an increase in the development of common infections resistant to last-resort antibiotics. Therefore, in the coming years, the demand for onychomycosis treatment would increase, which will expedite the growth of the regional market.

The China market dominated the Asia Pacific Onychomycosis Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $328.1 Million by 2028. The Japan market is estimated to grow a CAGR of 5% during (2022 - 2028). Additionally, The India market would experience a CAGR of 6.3% during (2022 - 2028).

Based on Type, the market is segmented into Distal Subungual, Proximal Subungual, White Superficial and Others. Based on Treatment, the market is segmented into Topical, Oral and Others. Based on countries, the market is segmented into China, Japan, India, Australia, South Korea, Singapore, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Abbott Laboratories, Bausch Health Companies, Inc., Bayer AG, Cipla Limited, Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., and GlaxoSmithKline PLC.

Scope of the Study

Market Segments covered in the Report:

By Type

  • Distal Subungual
  • Proximal Subungual
  • White Superficial
  • Others

By Treatment

  • Topical
  • Oral
  • Others

By Country

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Singapore
  • Rest of Asia Pacific

Companies Profiled

  • Pfizer, Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Abbott Laboratories
  • Bausch Health Companies, Inc.
  • Bayer AG
  • Cipla Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • GlaxoSmithKline PLC

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Asia Pacific Onychomycosis Market, by Type
    • 1.4.2 Asia Pacific Onychomycosis Market, by Treatment
    • 1.4.3 Asia Pacific Onychomycosis Market, by Country
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition & Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Asia Pacific Onychomycosis Market by Type

  • 3.1 Asia Pacific Distal Subungual Market by Country
  • 3.2 Asia Pacific Proximal Subungual Market by Country
  • 3.3 Asia Pacific White Superficial Market by Country
  • 3.4 Asia Pacific Others Market by Country

Chapter 4. Asia Pacific Onychomycosis Market by Treatment

  • 4.1 Asia Pacific Topical Market by Country
  • 4.2 Asia Pacific Oral Market by Country
  • 4.3 Asia Pacific Others Market by Country

Chapter 5. Asia Pacific Onychomycosis Market by Country

  • 5.1 China Onychomycosis Market
    • 5.1.1 China Onychomycosis Market by Type
    • 5.1.2 China Onychomycosis Market by Treatment
  • 5.2 Japan Onychomycosis Market
    • 5.2.1 Japan Onychomycosis Market by Type
    • 5.2.2 Japan Onychomycosis Market by Treatment
  • 5.3 India Onychomycosis Market
    • 5.3.1 India Onychomycosis Market by Type
    • 5.3.2 India Onychomycosis Market by Treatment
  • 5.4 Australia Onychomycosis Market
    • 5.4.1 Australia Onychomycosis Market by Type
    • 5.4.2 Australia Onychomycosis Market by Treatment
  • 5.5 South Korea Onychomycosis Market
    • 5.5.1 South Korea Onychomycosis Market by Type
    • 5.5.2 South Korea Onychomycosis Market by Treatment
  • 5.6 Singapore Onychomycosis Market
    • 5.6.1 Singapore Onychomycosis Market by Type
    • 5.6.2 Singapore Onychomycosis Market by Treatment
  • 5.7 Rest of Asia Pacific Onychomycosis Market
    • 5.7.1 Rest of Asia Pacific Onychomycosis Market by Type
    • 5.7.2 Rest of Asia Pacific Onychomycosis Market by Treatment

Chapter 6. Company Profiles

  • 6.1 Abbott Laboratories
    • 6.1.1 Company Overview
    • 6.1.2 Financial Analysis
    • 6.1.3 Segmental and Regional Analysis
    • 6.1.4 Research & Development Expense
    • 6.1.5 SWOT Analysis
  • 6.2 Bausch Health Companies, Inc.
    • 6.2.1 Company Overview
    • 6.2.2 Financial Analysis
    • 6.2.3 Segmental and Regional Analysis
    • 6.2.4 Research & Development Expense
    • 6.2.5 Recent strategies and developments:
      • 6.2.5.1 Trials and Approvals:
  • 6.3 Bayer AG
    • 6.3.1 Company Overview
    • 6.3.2 Financial Analysis
    • 6.3.3 Segmental and Regional Analysis
    • 6.3.4 Research & Development Expense
    • 6.3.5 Recent strategies and developments:
      • 6.3.5.1 Product Launches and Expansions:
  • 6.4 Cipla Limited
    • 6.4.1 Company Overview
    • 6.4.2 Financial Analysis
    • 6.4.3 Regional Analysis
    • 6.4.4 Research & Development Expense
    • 6.4.5 Recent strategies and developments:
      • 6.4.5.1 Product Launches and Product Expansions:
  • 6.5 Sun Pharmaceutical Industries Ltd.
    • 6.5.1 Company Overview
    • 6.5.2 Financial Analysis
    • 6.5.3 Regional & Segmental Analysis
    • 6.5.4 Research & Development Expenses
    • 6.5.5 Recent strategies and developments:
      • 6.5.5.1 Acquisition and Mergers:
  • 6.6 GlaxoSmithKline PLC (GSK)
    • 6.6.1 Company Overview
    • 6.6.2 Financial Analysis
    • 6.6.3 Segmental and Regional Analysis
    • 6.6.4 Research & Development Expense
    • 6.6.5 Recent strategies and developments:
      • 6.6.5.1 Partnerships, Collaborations, and Agreements:
  • 6.7 Pfizer, Inc.
    • 6.7.1 Company Overview
    • 6.7.2 Financial Analysis
    • 6.7.3 Regional & Segmental Analysis
    • 6.7.4 Research & Development Expense
  • 6.8 Teva Pharmaceutical Industries Ltd.
    • 6.8.1 Company Overview
    • 6.8.2 Financial Analysis
    • 6.8.3 Regional Analysis
    • 6.8.4 Research & Development Expenses
  • 6.9 Merck & Co., Inc.
    • 6.9.1 Company Overview
    • 6.9.2 Financial Analysis
    • 6.9.3 Segmental and Regional Analysis
    • 6.9.4 Research & Development Expenses
  • 6.10. Novartis AG
    • 6.10.1 Company Overview
    • 6.10.2 Financial Analysis
    • 6.10.3 Segmental and Regional Analysis
    • 6.10.4 Research & Development Expense

LIST OF TABLES

  • TABLE 1 Asia Pacific Onychomycosis Market, 2018 - 2021, USD Million
  • TABLE 2 Asia Pacific Onychomycosis Market, 2022 - 2028, USD Million
  • TABLE 3 Asia Pacific Onychomycosis Market by Type, 2018 - 2021, USD Million
  • TABLE 4 Asia Pacific Onychomycosis Market by Type, 2022 - 2028, USD Million
  • TABLE 5 Asia Pacific Distal Subungual Market by Country, 2018 - 2021, USD Million
  • TABLE 6 Asia Pacific Distal Subungual Market by Country, 2022 - 2028, USD Million
  • TABLE 7 Asia Pacific Proximal Subungual Market by Country, 2018 - 2021, USD Million
  • TABLE 8 Asia Pacific Proximal Subungual Market by Country, 2022 - 2028, USD Million
  • TABLE 9 Asia Pacific White Superficial Market by Country, 2018 - 2021, USD Million
  • TABLE 10 Asia Pacific White Superficial Market by Country, 2022 - 2028, USD Million
  • TABLE 11 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
  • TABLE 12 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
  • TABLE 13 Asia Pacific Onychomycosis Market by Treatment, 2018 - 2021, USD Million
  • TABLE 14 Asia Pacific Onychomycosis Market by Treatment, 2022 - 2028, USD Million
  • TABLE 15 Asia Pacific Topical Market by Country, 2018 - 2021, USD Million
  • TABLE 16 Asia Pacific Topical Market by Country, 2022 - 2028, USD Million
  • TABLE 17 Asia Pacific Oral Market by Country, 2018 - 2021, USD Million
  • TABLE 18 Asia Pacific Oral Market by Country, 2022 - 2028, USD Million
  • TABLE 19 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
  • TABLE 20 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
  • TABLE 21 Asia Pacific Onychomycosis Market by Country, 2018 - 2021, USD Million
  • TABLE 22 Asia Pacific Onychomycosis Market by Country, 2022 - 2028, USD Million
  • TABLE 23 China Onychomycosis Market, 2018 - 2021, USD Million
  • TABLE 24 China Onychomycosis Market, 2022 - 2028, USD Million
  • TABLE 25 China Onychomycosis Market by Type, 2018 - 2021, USD Million
  • TABLE 26 China Onychomycosis Market by Type, 2022 - 2028, USD Million
  • TABLE 27 China Onychomycosis Market by Treatment, 2018 - 2021, USD Million
  • TABLE 28 China Onychomycosis Market by Treatment, 2022 - 2028, USD Million
  • TABLE 29 Japan Onychomycosis Market, 2018 - 2021, USD Million
  • TABLE 30 Japan Onychomycosis Market, 2022 - 2028, USD Million
  • TABLE 31 Japan Onychomycosis Market by Type, 2018 - 2021, USD Million
  • TABLE 32 Japan Onychomycosis Market by Type, 2022 - 2028, USD Million
  • TABLE 33 Japan Onychomycosis Market by Treatment, 2018 - 2021, USD Million
  • TABLE 34 Japan Onychomycosis Market by Treatment, 2022 - 2028, USD Million
  • TABLE 35 India Onychomycosis Market, 2018 - 2021, USD Million
  • TABLE 36 India Onychomycosis Market, 2022 - 2028, USD Million
  • TABLE 37 India Onychomycosis Market by Type, 2018 - 2021, USD Million
  • TABLE 38 India Onychomycosis Market by Type, 2022 - 2028, USD Million
  • TABLE 39 India Onychomycosis Market by Treatment, 2018 - 2021, USD Million
  • TABLE 40 India Onychomycosis Market by Treatment, 2022 - 2028, USD Million
  • TABLE 41 Australia Onychomycosis Market, 2018 - 2021, USD Million
  • TABLE 42 Australia Onychomycosis Market, 2022 - 2028, USD Million
  • TABLE 43 Australia Onychomycosis Market by Type, 2018 - 2021, USD Million
  • TABLE 44 Australia Onychomycosis Market by Type, 2022 - 2028, USD Million
  • TABLE 45 Australia Onychomycosis Market by Treatment, 2018 - 2021, USD Million
  • TABLE 46 Australia Onychomycosis Market by Treatment, 2022 - 2028, USD Million
  • TABLE 47 South Korea Onychomycosis Market, 2018 - 2021, USD Million
  • TABLE 48 South Korea Onychomycosis Market, 2022 - 2028, USD Million
  • TABLE 49 South Korea Onychomycosis Market by Type, 2018 - 2021, USD Million
  • TABLE 50 South Korea Onychomycosis Market by Type, 2022 - 2028, USD Million
  • TABLE 51 South Korea Onychomycosis Market by Treatment, 2018 - 2021, USD Million
  • TABLE 52 South Korea Onychomycosis Market by Treatment, 2022 - 2028, USD Million
  • TABLE 53 Singapore Onychomycosis Market, 2018 - 2021, USD Million
  • TABLE 54 Singapore Onychomycosis Market, 2022 - 2028, USD Million
  • TABLE 55 Singapore Onychomycosis Market by Type, 2018 - 2021, USD Million
  • TABLE 56 Singapore Onychomycosis Market by Type, 2022 - 2028, USD Million
  • TABLE 57 Singapore Onychomycosis Market by Treatment, 2018 - 2021, USD Million
  • TABLE 58 Singapore Onychomycosis Market by Treatment, 2022 - 2028, USD Million
  • TABLE 59 Rest of Asia Pacific Onychomycosis Market, 2018 - 2021, USD Million
  • TABLE 60 Rest of Asia Pacific Onychomycosis Market, 2022 - 2028, USD Million
  • TABLE 61 Rest of Asia Pacific Onychomycosis Market by Type, 2018 - 2021, USD Million
  • TABLE 62 Rest of Asia Pacific Onychomycosis Market by Type, 2022 - 2028, USD Million
  • TABLE 63 Rest of Asia Pacific Onychomycosis Market by Treatment, 2018 - 2021, USD Million
  • TABLE 64 Rest of Asia Pacific Onychomycosis Market by Treatment, 2022 - 2028, USD Million
  • TABLE 65 Key Information - Abbott Laboratories
  • TABLE 66 key information - Bausch Health Companies, Inc.
  • TABLE 67 Key Information - Bayer AG
  • TABLE 68 Key Information - Cipla Limited
  • TABLE 69 Key Information - Sun Pharmaceutical Industries Ltd.
  • TABLE 70 Key Information - GlaxoSmithKline PLC (GSK)
  • TABLE 71 Key Information - Pfizer, Inc.
  • TABLE 72 Key Information - Teva Pharmaceuticals Industries Ltd.
  • TABLE 73 KEY INFORMATION - Merck & Co., Inc.
  • TABLE 74 Key Information - Novartis AG

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 Swot analysis: Abbott laboratories
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!